Cerebrolysin

Mechanism of action

Cerebrolysin is a complex multi-component preparation produced by Ever Pharma (Austria) through controlled enzymatic hydrolysis of lipid-free, standardised young porcine brain tissue. The final product is a sterile aqueous solution containing approximately 25% peptides of molecular weight below 10 kDa (including small biologically active peptides, neurotrophic-factor fragments, and peptide hormone fragments) and approximately 75% free amino acids. The compositional standardisation is achieved through controlled hydrolysis parameters and quality-control testing, but the preparation is fundamentally a complex mixture rather than a single defined peptide molecule — a critical mechanistic distinction from the other research peptides on this site. The mechanistic pharmacology of cerebrolysin is consequently multi-pathway rather than single-target. The principal documented effects include: pleiotropic neurotrophic activity (functional mimicry of nerve growth factor NGF, brain-derived neurotrophic factor BDNF, glial-cell-derived neurotrophic factor GDNF, and ciliary neurotrophic factor CNTF — likely mediated by small peptide components with structural similarity to bioactive fragments of these neurotrophins); neuroprotective effects on excitotoxic and oxidative-stress-mediated neuronal damage (relevant to acute stroke and traumatic brain injury models); modulation of amyloid precursor protein processing toward non-amyloidogenic pathways (relevant to Alzheimer's-disease applications); modulation of neuroinflammation through downregulation of pro-inflammatory cytokine expression; and direct stimulation of synaptic protein synthesis, dendritic-spine formation, and adult hippocampal neurogenesis. The multi-pathway pharmacology is the defining feature distinguishing cerebrolysin from single-target research peptides. Different molecular components of the preparation address different pathways simultaneously, producing an integrated effect that is mechanistically difficult to attribute to specific molecular entities. This pleiotropic nature has been simultaneously cerebrolysin's principal scientific strength (the clinical evidence base is substantial and the pharmacology addresses multiple mechanistic targets relevant to stroke, dementia, and TBI) and its principal regulatory weakness (Western regulatory frameworks, particularly FDA, prefer single-defined-molecule pharmacology with clear receptor/target identification, complicating Western registration prospects). The clinical-evidence base spans 50+ years of European, Russian, and Asian use across acute ischaemic stroke (timing-dependent neuroprotective effects), traumatic brain injury (multi-week treatment courses for functional recovery), vascular dementia (chronic intermittent dosing protocols), Alzheimer's disease (similar chronic intermittent dosing), and Rett syndrome (pediatric neurodevelopmental application). Multiple Cochrane reviews and meta-analyses have examined the evidence quality. The CASTA acute stroke trial (Heiss et al., Stroke 2012) — a Western-standard Phase III RCT — did not meet its primary endpoint, but post-hoc analyses suggested benefit in moderate-severity strokes and the overall evidence base remains net positive across the various indications. Delivery is exclusively parenteral — the multi-component preparation is not oral-bioavailable in any clinically meaningful way, and the licensed treatment protocols use intravenous infusion (slow infusion of 5-50 mL diluted preparation over 15-60 minutes) or intramuscular injection. Treatment courses are typically 10-20 daily administrations, sometimes repeated at 3-6 month intervals for chronic indications.

Cerebrolysin has accumulated 50+ years of clinical use across 50+ countries with millions of patient exposures — perhaps the largest cumulative real-world safety dataset of any compound on this site — without surfacing documented porcine-source disease transmission or significant chronic-exposure safety signals. The principal evidence-base contest is about efficacy (the CASTA acute-stroke Phase III did not meet its primary endpoint) rather than safety, which has shaped Western regulatory caution.

— Notable finding

Research history

Cerebrolysin was developed by Ebewe Pharmaceuticals (Austria) — subsequently acquired by Ever Pharma — beginning in the 1950s and 1960s, with first market approvals in Austria and several Central European countries from the late 1960s. The compound's development predates much of modern peptide pharmacology and reflects an earlier era of biological-source drug development where compositional standardisation rather than single-molecule definition was the regulatory framework. The CAS registration (12656-61-0) reflects this multi-component preparation status rather than a single defined chemical entity. The compound has been progressively registered as a prescription medicine in 50+ countries across Europe, Russia, the Commonwealth of Independent States, China, India, several Latin American countries, and parts of Southeast Asia, accumulating a very substantial clinical-use record over five decades. Indications have evolved alongside the broader neurology landscape — initial focus on stroke neuroprotection (acute and post-acute), then expansion to traumatic brain injury, vascular dementia, Alzheimer's disease, and various developmental and degenerative neurological conditions. Western (FDA, EMA, MHRA) regulatory authorisation has not been achieved. The CASTA acute stroke trial (Heiss et al., Stroke 2012), a Western-standard Phase III randomised controlled trial in 1,070 acute ischaemic stroke patients across European sites, was the principal attempt to establish Western evidence. The primary composite endpoint did not reach statistical significance, though post-hoc analyses identified efficacy signals in moderate-severity stroke subgroups. The result has been interpreted variously: cerebrolysin proponents emphasise the post-hoc moderate-severity benefit and the consistent positive evidence across other indications; sceptics emphasise the negative primary endpoint and the methodological challenges of multi-component preparation pharmacology. A 2020 Cochrane review on cerebrolysin in acute ischaemic stroke (with 7 RCTs, 1,773 participants total) concluded that the available evidence does not support efficacy and that several included trials had methodological limitations. Other Cochrane reviews on vascular dementia and Alzheimer's disease have reached similarly cautious conclusions. The cerebrolysin evidence base is therefore extensive but contested — a status that has prevented Western regulatory adoption while not affecting the established clinical use in registered jurisdictions. In the UK in 2025-2026, cerebrolysin is not available as a licensed medicine. Specialist access through the unlicensed-medicines 'specials' route is theoretically possible for individual patients (typically through importation from European pharmacies) but is rarely pursued in practice. Research-chemical-grade material is occasionally available from Western suppliers but the multi-component nature complicates research-grade quality assurance.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Cerebrolysin has perhaps the largest cumulative real-world safety dataset of any compound in this site, accumulated through 50+ years of clinical use across 50+ countries and millions of patient exposures. The reported adverse-event profile is favourable: mild and transient adverse effects predominate. Acute infusion-related effects include occasional sensation of heat or sweating during infusion, mild dizziness, and rare reports of headache. The intravenous formulation has documented occasional injection-site reactions and rare hypersensitivity events (skin reactions, anaphylaxis is uncommon but reported in product information). No clinically significant changes in routine haematology, biochemistry, or vital signs are documented at therapeutic doses. The principal theoretical safety consideration is the porcine biological-source origin of the preparation. Theoretical concerns about porcine viral or prion contamination have been addressed through the standardised manufacturing process (lipid-free preparation, controlled enzymatic hydrolysis, filtration, and quality-control testing); no documented cases of porcine-source disease transmission have been associated with cerebrolysin use across its long clinical history. Religious and ethical considerations regarding the porcine source are individual matters that may affect patient acceptance in certain populations. Long-term safety is well-characterised by the 50+ year clinical-use history. The cumulative real-world data have not surfaced concerning signals for malignancy, cardiovascular events, or other organ-specific toxicities at therapeutic dose tiers. Chronic intermittent dosing protocols (multi-week courses repeated at intervals) have produced no documented cumulative-exposure adverse-event patterns. The principal practical 'safety' constraint is therefore not adverse events from cerebrolysin itself but the regulatory and quality-assurance complications of unlicensed UK use. UK individuals obtaining cerebrolysin through unauthorised channels face supply-chain integrity uncertainty (counterfeit risk), administration-error risks without medical supervision, and the broader regulatory exposure of using unlicensed medicines outside the 'specials' framework. No serious cerebrolysin-specific adverse events have been documented at standard therapeutic doses across the 50+ year experience. The acute and chronic safety record is favourable; the evidence-base limitations are about efficacy rather than safety.

UK regulatory status

Cerebrolysin is **NOT** authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no UK marketing authorisation. The compound is registered as a prescription medicine in 50+ countries (most of continental Europe, Russia, CIS, China, India, several Latin American and Asian countries) but neither the UK, US, nor Canada has authorised it. It is not a controlled substance under the Misuse of Drugs Act 1971. Possession of research-grade material for bona fide in-vitro and animal research is generally unrestricted in the UK. Supply or administration of cerebrolysin to humans outside an authorised UK clinical-trial framework engages the Human Medicines Regulations 2012 — registration in other countries does NOT authorise UK supply or use. Specialist UK access through the unlicensed-medicines 'specials' route (Regulation 167 of the Human Medicines Regulations 2012) is theoretically possible for individual patients with neurological indications, typically through a named prescriber arrangement and importation from European pharmacies. In practice this is rarely pursued given the absence of UK clinical-prescribing infrastructure familiar with cerebrolysin and the broader practical and cost complications of imported specialist medicines. Cerebrolysin is not currently on the WADA Prohibited List. Its complex multi-component composition complicates clean WADA classification but no specific named-substance prohibition exists. For animal research under ASPA, cerebrolysin work in vertebrates requires standard project and personal licences. The multi-component nature complicates exact reproduction of research-grade preparation across animal studies; Ever Pharma-supplied clinical-grade material is the typical research reference standard.

Frequently asked questions